Plain-English translation of NCT06700369 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether people with HER2-positive breast cancer can be treated with a simpler chemotherapy regimen before surgery. Currently, doctors use a combination of two chemotherapy drugs (a taxane plus carboplatin) along with two targeted medications (trastuzumab and pertuzumab). This study asks whether using just one chemotherapy drug—a taxane—with the same targeted medications might work just as well while causing fewer side effects.
Combination chemotherapy can cause serious side effects and be hard on the body. Doctors want to know if the targeted medications are powerful enough to do most of the work, allowing patients to skip the second chemotherapy drug and still get excellent results.
You likely qualify if…
You likely don't qualify if…
You would receive one of two chemotherapy regimens before your breast cancer surgery, combined with targeted medications. Both approaches involve 6 cycles of treatment given over several months at the hospital. The main difference is whether your chemotherapy includes one drug or two drugs, though both groups receive the same targeted medications. Researchers will track how well the treatment works and what side effects you experience, using your hospital records and data from the hospital's research database.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
China